Retatrutide, by Soma Pharmaceuticals , is attracting increasing attention as a innovative method for weight management . This dual-action drug merges the activity of a GLP-1 receptor activator and a GIP receptor agonist , aiming to simply promote metabolic improvements but also improve underlying metabolic factors. Initial clinical data have shown